^
    Back
    Association details:
    Biomarker:KRAS G12C + PD-L1 underexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ELCC 2022
    Title:

    Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic nonsquamous NSCLC with PD-L1 low

    Published date:
    03/23/2022
    Excerpt:
    In the context of chemo-IO combo, our study aims to compare platinum-pemetrexed-pembrolizumab (PPP) combo to platinum-doublet alone in pts with low PD-L1 (<50%)…KRAS G12C was associated with better PFS (HR 0.33, 95%CI 0.11-1.04).
    Secondary therapy:
    pemetrexed